Urinary Pharmacokinetics and Theoretical Pharmacodynamics of Intravenous Levofloxacin in Intensive Care Unit Patients Treated with 500 mg b.i.d. for Ventilator-Associated Pneumonia

Journal of Chemotherapy

Volumn 15, Issue 6, 2003, Pages 563-567

  Pea, F ^a   Pavan, F ^a   Di Qual, E ^a   Brollo, L ^a   Nascimben, E ^b   Baldassarre, M ^c   Furlanut, M ^a  

^a UNIVERSITY OF UDINE   (Italy)

^b CA FONCELLO HOSPITAL   (Italy)

^c SANTA MARIA DELLA MISERICORDIA UNIVERSITY HOSPITAL   (Italy)

Author keywords

ICU patients; Levofloxacin; Pharmacokinetics; Urine

Indexed keywords

ANTIINFECTIVE AGENT; CREATININE; LEVOFLOXACIN;

ADULT; AREA UNDER THE CURVE; ARTICLE; BACTERICIDAL ACTIVITY; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE CLEARANCE; DEVICE INFECTION; DIURESIS; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG EXCRETION; DRUG URINE LEVEL; FEMALE; HUMAN; INTENSIVE CARE UNIT; KIDNEY FUNCTION; MALE; MINIMUM INHIBITORY CONCENTRATION; PHARMACODYNAMICS; PNEUMONIA; STEADY STATE; URINALYSIS; URINARY EXCRETION; VENTILATOR;

EID: 1242317738     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2003.15.6.563     Document Type: Article

References (15)

1. Drago L, De Vecchi E, Mombelli B, Nicola L, Valli M, Gismondo MR. Activity of levofloxacin and ciprofloxacin against urinary pathogens. J Antimicrob Chemother 2001; 48 (1): 37-45.
2. Martin SJ, Jung R, Garvin CG. A risk-benefit assessment of levofloxacin in respiratory, skin and skin structure, and urinary tract infections. Drug Saf 2001; 24 (3): 199-222.
3. Naber KG. Which fluoroquinolones are suitable for the treatment of urinary tract infections? Int J Antimicrob Agents 2001; 17 (4): 331-341.
4. Richards MJ, Edwards JR, Culver DH, Gaynes RP. Nosocomial infections in medical intensive care units in the United States. National Nosocomial Infections Surveillance System. Crit Care Med 1999; 27 (5): 887-892.
5. Pea F, Di Qual E, Cusenza A, Brollo L, Baldassarre M, Furlanut M. Pharmacokinetics and pharmacodynamics of levofloxacin 500 mg bid IV in ICU patients with early-onset ventilator-associated pneumonia. Clin Pharmacokinet 2003; 42 (6): 589-598.
6. Pea F, Pavan F, Nascimben E, et al. Levofloxacin disposition in cerebrospinal fluid of patients with external ventriculostomy. Antimicrob Agents Chemother 2003; 47 (10): 3104-3109.
7. Rowland M, Tozer TN, Clinial Pharmacokinetics. Concepts and applications. 3rd ed Williams & Wilkins. 1995
8. Preston SL, Drusano GL, Berman AL, et al. Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. Jama 1998; 279 (2): 125-129.
9. Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ. Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993; 37 (5): 1073-1081.
10. Glantz SA, Primer of biostatistics. 5th ed McGraw Hill. 2002
11. Naber CK, Hammer M, Kinzig-Schippers M, Sorgel F, Naber KG. Urinary excretion and bactericidal activities of levofloxacin versus ciprofloxacin in healthy volunteers after a single oral dose of 500 mg. Abstract at the 9th Int Congress of Infectious Diseases, Buenos Aires Argentina 2000; Poster 10920.
12. Costerton JW. Introduction to biofilm. Int J Antimicrob Agents 1999; 11 (3-4): 217-221.
13. Goto T, Nakame Y, Nishida M, Ohi Y. Bacterial biofilms and catheters in experimental urinary tract infection. Int J Antimicrob Agents 1999; 11 (3-4): 227-231.
14. NCCLS. Performance standards for antimicrobial susceptibility testing: twelth informational supplement. 2002; 22: M100-S12
15. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16 (1): 31-41.